0      0


AM22-13-O - AM22-13-O: (On-Demand) Effects of Transfusion on Bone Marrow Health and Transplant Outcomes in Sickle Cell Disease (Enduring)


‐ Nov 7, 2022 6:00pm

Expiration Date: Dec 31, 2024


Credits: None available.

Bone marrow pathology in SCD, such as decreased mesenchymal stem cell function and disordered vasculature, has recently been described in pre-clinical models and has been shown to be responsive to red cell transfusion. A speaker will review her and others’ research in this area and its implications for peri-transplant transfusion support. Another speaker will discuss the association of HLA and red cell alloantibodies with important allogeneic transplant outcomes in SCD such as graft versus host disease, donor T cell chimerism, and even overall survival. Both speakers will speak to the implication of these findings for best practice transfusion support for SCD patients pre- and peri-transplant.

All relevant financial relationships have been mitigated.


Learning Objectives:

  • Describe the potential of transfusion to improve allogeneic transplant and gene therapy outcomes in SCD through its effects on the bone marrow microenvironment.
  • Describe the association of HLA and red cell alloantibodies with allogeneic transplant outcomes in SCD.
  • Discuss best practice of transfusion support for SCD patients pre- and peri-transplant in the autologous and allogeneic setting.

Disclosures

  • Patricia Shi, MD:
    Global Blood Therapeutics: Grant/Research Support (Secondary Investigators need not disclose)
  • Robert Nickel, MD:
    Nothing to Disclose
  • Avital Mendelson, PhD:

    Nothing to disclose

By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.

Credits Available


AM22-13-O: (On-Demand) Effects of Transfusion on Bone Marrow Health and Transplant Outcomes in Sickle Cell Disease (Enduring) Evaluation